Canakinumab (ILARIS) is an innovative biotherapeutic drug that is playing an increasingly important role in the medical field. It is mainly used to treat a variety of inflammatory diseases, bringing new therapeutic hope to many patients. Understanding the population eligible for canakinumab is of great significance for guiding clinical medication use and ensuring the efficacy and safety of the drug.

Eligible Populations for Canakinumab (ILARIS)

Adult patients: 

Canakinumab is widely applicable to adult patients, especially those suffering from periodic fever syndromes (such as CAPS), systemic juvenile idiopathic arthritis (although it usually occurs in children, adults may also suffer from it), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, familial Mediterranean fever and other diseases. These diseases are often accompanied by severe inflammatory reactions and pain. Canakinumab can effectively alleviate these symptoms and improve patients' quality of life by inhibiting the activity of interleukin-1β (IL-1β).

Pediatric and adolescent patients: 

Canakinumab is also applicable to pediatric and adolescent patients aged 4 years and older. For children with periodic fever syndromes, systemic juvenile idiopathic arthritis and other diseases, canakinumab provides an effective treatment option. Clinical trials have shown that the efficacy and safety of canakinumab in pediatric and adolescent patients are comparable to those in adults, and it can significantly improve the disease symptoms and signs of patients.

Special populations: 

In addition to adult, pediatric and adolescent patients, canakinumab may also be applicable to certain special populations. For example, for pregnant and lactating women, although there is limited data on the use of canakinumab in these populations, when necessary, doctors may decide whether to use canakinumab after weighing the pros and cons according to the patient's specific situation and the severity of the disease. Since the impact of canakinumab in breast milk and the potential systemic exposure in breastfed infants are not clear, lactating women should use canakinumab with caution.